Quest Diagnostics introduces innovative at-home blood test for early Alzheimer's detection

Quest Diagnostics has launched the first blood-based biomarker test, called AD-Detect, to assess the risk of developing Alzheimer's disease. The test evaluates the ratio of two peptides of amyloid beta in plasma, which helps assess the risk based on the brain protein's contribution to the disease. With emerging treatments and growing recognition of non-pharmacological interventions, there is increasing acceptance of blood tests for early detection. The number of Americans diagnosed with Alzheimer's is expected to reach 14 million by 2060.